IP boutique Carpmaels & Ransford is among the elite firms in Europe for patent prosecution work in the chemistry and life sciences sectors. The firm also has a strong patent protection team in fields such as engineering and computer technology. There are several recommended European patent attorneys in the firm; they include Edward Oates, Gary Small, Daniel Wise, James Warner, Mark Chapman, Cameron Marshall, John Brunner, Susan Kirsch and Hugh Goodfellow. Kirsch, who is highly rated in EPO proceedings, is also featured in Managing IP's Top 250 Women in IP (2019) publication.
The firm further strengthened its life sciences practice in 2018 by hiring patent star Harvey Adams as a partner. European patent attorneys Stephen Duffield and Christopher Hoggett, who were commended in the 2018 edition of IP STARS, were promoted to partner in July 2019. Another newly promoted partner to watch is Matthew Georgiou. Associates Natalia Wegner-Cribbs, Daniel Goodman and Isobel Barry are among the rising stars in the patent attorney team. John Fisher, who was also commended in the 2018 edition, joined another IP firm as a partner in January 2019.
Patent prosecution case studies show the team dealing with EPO oppositions and appeals for companies such as Biosense Webster, Merck Sharp & Dohme and Regeneron Pharmaceuticals. Janssen and Gilead Sciences are among the companies the team advises on SPC protection in Europe. The team won Managing IP's UK Firm of the Year (2019) award for patent prosecution work.
The patent disputes team remains active in and outside the English courts, recently handling disputes for companies such as Celgene Corporation, Arc Medical Design and Align Technology. The key litigators in the team are David Wilson, Camilla Balleny and Ian Kirby. Clients in need of IP transactions advice can go to Jake Marshall. Jennifer Antcliff is a rising star in the litigation team. Another litigation associate to watch is Simon Llewellyn, who joined the firm in 2018. Patent litigation case studies show the team acted for Abraxis Bioscience in a dispute in which the CJEU clarified whether an SPC may be granted for new formulations of old active ingredients.